Net loss: US$269.9m (loss widened by 14% from FY 2023). US$3.98 loss per share. Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 24%. Looking ahead ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $41.75 average price target. Vertex Pharmaceuticals NewsMORE Related Stocks ...

--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare ...

provides cash runway into the second half of 2027 - Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

Viridian Therapeutics, Inc. (VRDN) reported Q4 EPS of ($1.13), versus $1.31 reported last year. Revenue for the quarter came in at $105 thousand, versus $214 thousand reported last ...

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) traded down 4% during trading on Monday .The company traded as low as $3.52 and last traded at $3.57. 254,081 shares were ...

Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -3.77 and a beta of 1.32.